Methocarbamol CRI

Centrally acting skeletal muscle relaxant. Exact mechanism not fully characterized; produces general CNS depression rather than direct action on skeletal muscle or the neuromuscular junction. Onset 5–10 minutes IV; duration highly variable (1–4 hours after bolus). Hepatic metabolism with renal elimination of metabolites. PEG-300 vehicle in the injectable adds renal-clearance dependence.

Open calculator →

Clinical background

Methocarbamol is a central-acting skeletal muscle relaxant used in vet ICU primarily for the treatment of tremorogenic toxicoses (pyrethrin and permethrin toxicity, tremorgenic mycotoxins from moldy food, metaldehyde, strychnine) and as adjunct therapy in tetanus. The clinical pivot is that methocarbamol controls the muscle activity that drives the morbidity of these poisonings without producing the respiratory depression of barbiturates or the cardiovascular instability of phenothiazines. The CRI matters in the patients who continue tremoring through the duration of toxin elimination, which can stretch to 24–72 hours for the lipophilic pyrethroids.

Pharmacology

The exact mechanism of methocarbamol’s muscle relaxant effect is not fully characterized, but the active site is central rather than at the neuromuscular junction. Proposed mechanisms include:

• Polysynaptic spinal reflex inhibition, reducing the excitability of motor neuron pools that drive sustained muscle contraction
• Brainstem reticular formation depression, modulating descending excitatory pathways
• Possible weak GABAergic potentiation, though less prominent than with benzodiazepines or barbiturates

What methocarbamol does not do: it does not block the neuromuscular junction directly (it is not a paralytic), it does not produce significant analgesia, and it has minimal anxiolytic effect beyond what the muscle relaxation itself produces.

Onset is within 5–30 minutes after IV administration. Duration after a single IV bolus is 2–4 hours. Half-life is approximately 1–2 hours in dogs. Hepatic metabolism via dealkylation and hydroxylation produces inactive metabolites; renal excretion of these metabolites is the principal clearance route.

The IV formulation is dissolved in polyethylene glycol 300 (PEG 300), which is a clinically important vehicle in two contexts. First, PEG 300 is osmotically active and renally excreted; accumulation in patients with reduced GFR can produce hyperosmolar effects. Second, PEG 300 is mildly irritating to peripheral veins at higher concentrations and prolonged infusions; phlebitis is a not-uncommon late complication of multi-day CRIs.

Indications

Primary use cases:

• Pyrethrin and permethrin toxicity in cats. The most common emergency methocarbamol indication. Topical exposure (most often dog flea-and-tick product applied accidentally to a cat) produces tremors, hyperthermia, hypersalivation, and progression to seizures in severe cases. The duration of toxicity is determined by the lipophilic distribution and slow redistribution out of fat stores; treatment can span 24–72 hours.
• Tremorgenic mycotoxin ingestion. Dogs eating moldy food (commonly garbage or compost) ingest penitrem A and other tremorgens that produce sustained whole-body tremors lasting 24–72 hours. Methocarbamol controls the tremors; activated charcoal and lipid emulsion address the toxin.
• Strychnine and other rodenticide toxicities producing strong tetanic muscle activity. Methocarbamol is part of the supportive care alongside decontamination and seizure control.
• Metaldehyde toxicity (slug and snail bait), where the tremors and seizures can be severe and sustained. Methocarbamol contributes to muscle activity control.
• Tetanus, generalized form. Wound-acquired Clostridium tetani infection produces severe muscle rigidity and reflex spasms. Methocarbamol is an adjunct to antitoxin, antibiotics, and wound care; the muscle spasm control is a major contribution to survival in the severe cases.
• Inadvertent intrathecal contrast or chemical exposure producing muscle spasm, less common.

The CRI is used when intermittent bolus dosing is not maintaining tremor control through the duration of the toxin’s effect. For shorter toxicoses (most metaldehyde, strychnine if treated promptly) intermittent boluses are sufficient; for the longer toxicoses (pyrethroids, mycotoxins) the CRI is the right tool.

Methocarbamol is not analgesic; muscle relaxation reduces pain that arises from sustained spasm but does not address pain from other sources. In tetanus, opioid analgesia is part of the protocol.

Dosing

• Dogs and cats, CRI: 5–15 mg/kg/hr, titrated against tremor activity.
• Initial maintenance rate: 5–10 mg/kg/hr.
• Caution above: 12 mg/kg/hr. The dose-limiting concerns are excessive sedation, the daily-dose ceiling, and PEG accumulation in patients with renal compromise.
• Hard maximum daily dose: 330 mg/kg/day per Plumb’s. Continuous CRI at high rates can exceed this surprisingly quickly: 12 mg/kg/hr × 24 hours = 288 mg/kg/day, close to the ceiling. Reassess CRI rate and consider sequential 24-hour dose limits in patients whose tremors are extending toward multi-day duration.

Loading dose for active tremors or muscle spasm: 55–220 mg/kg IV slowly, given over 5–15 minutes. The wide range reflects the variable severity of presentation; 55 mg/kg is a common starting dose for moderate tremor activity, with repeat boluses of 55–110 mg/kg as needed up to the daily cap. For severe tetanus or severe pyrethroid toxicity with sustained tremors, the higher loading dose (150–220 mg/kg) is used initially.

Give the loading bolus slowly. Rapid IV push of methocarbamol can produce hypotension, syncope, and (rarely) seizures. The IV rate should not exceed 2 mL/min of the 100 mg/mL preparation, which for a 20 kg dog at 50 mg/kg loading dose means a 5 minute infusion.

Repeat loading boluses are timed by tremor recurrence, not by a fixed interval; if tremors resume 2 hours after the initial bolus, that is when the next bolus is appropriate, watching the cumulative daily total.

Cat dosing follows the same range. Cats with pyrethroid toxicity often require sustained CRI delivery for 24–48 hours because of the lipophilic distribution and slow redistribution out of fat stores.

Administration

Stock is 100 mg/mL injectable in a 20 mL vial (2000 mg per vial). The InfusionFox calculator preselects three weight-banded preparations (50, 20, or 10 mg/mL) to keep the pump rate in the precision range across patient size.

Diluent: 0.9% sodium chloride or 5% dextrose, both compatible. The PEG 300 vehicle in the stock is preserved in the diluted preparation but is less viscous and less irritating at the working concentration.

Compatibility is generally broad with most ICU drugs. Avoid mixing in the same line with:

• Sodium bicarbonate (precipitation at the PEG/bicarbonate interface)
• Calcium-containing solutions (precipitation)
• Highly acidic drugs

Methocarbamol does not require light protection. Stability is good at room temperature for the typical 24-hour hang time.

Phlebitis at the IV site can develop after 24–48 hours of peripheral infusion, particularly at higher concentrations. The 10 mg/mL working concentration is well tolerated peripherally; the 50 mg/mL preparation is best used through a central line. Rotate peripheral catheters every 48 hours during sustained CRIs.

Drug interactions

• CNS depressants (opioids, benzodiazepines, barbiturates, inhalant anesthetics, propofol) have additive sedation and respiratory depression with methocarbamol. This is sometimes the intended combination (opioid for tetanus pain plus methocarbamol for the muscle spasm); the implication is that the dose of each can be reduced.
• Cholinesterase inhibitors (pyridostigmine, neostigmine) can theoretically antagonize methocarbamol’s central muscle relaxant effect, though the clinical relevance is minor.
• Drugs with significant renal-dose-adjustment requirements can have those requirements amplified by the PEG vehicle accumulation; reassess concurrent drug dosing in renal compromise.
• Other muscle relaxants (succinylcholine, atracurium) produce additive paralysis and require careful coordination of dose and timing; combination is rarely intentional in vet ICU.

Adverse effects

• Sedation, dose-related. Some sedation is expected and contributes to the calming effect during tremor management; excessive sedation is dose-limiting.
• Ataxia and weakness at higher doses. Cats and small dogs can become recumbent on doses that would be unremarkable for larger dogs.
• Hypersalivation, more common in cats. Usually mild.
• Bradycardia and hypotension with rapid IV bolus delivery. Slow administration prevents most of this.
• Phlebitis at the peripheral IV site with prolonged use of higher-concentration preparations.
• PEG vehicle accumulation in renal dysfunction: hyperosmolar effects, including possible metabolic derangement, in patients with significantly reduced GFR. Most concerning during multi-day CRIs in oligoanuric patients.
• Tissue irritation on extravasation, mild to moderate. The PEG vehicle is irritating; treat extravasation conservatively with stop, aspiration, and local warm compresses.

Cat-specific considerations

Pyrethrin and permethrin toxicity in cats is the most common indication and deserves particular attention. The duration of toxicity is determined by the slow redistribution of these lipophilic compounds from fat stores; patients can require sustained tremor control for 24–72 hours.

The treatment package in pyrethroid-toxic cats:

• Decontamination with a mild dishwashing detergent bath (twice) to remove residual topical product. Repeat bathing throughout the first 24 hours as needed.
• Methocarbamol CRI for tremor control as outlined above
• Active cooling if hyperthermic; tremor activity drives the temperature, controlling the tremor controls the temperature
• IV fluid support for ongoing losses and hyperthermia management
• Intravenous lipid emulsion as adjunct toxicology reversal (see /ile for the protocol). The lipid sink helps redistribute the lipophilic pyrethroid away from sites of action.

The combination of methocarbamol CRI plus ILE plus standard supportive care has produced substantially improved outcomes in severe permethrin toxicity in cats compared to historical mortality with methocarbamol alone.

Monitoring

• Tremor activity assessed by observation at frequent intervals during titration. The goal is tremor suppression sufficient to allow normal breathing and prevent hyperthermia, not complete absence of all motor activity.
• Body temperature in tremor patients. Sustained tremoring produces hyperthermia; effective methocarbamol therapy resolves the hyperthermia.
• Respiratory rate and effort. Watch for the combination of effective tremor control and excessive sedation producing hypoventilation. This is the principal late-CRI concern.
• Mental status. Some sedation is expected; profound depression suggests dose reduction or PEG accumulation.
• IV site inspection every 4–6 hours for phlebitis or extravasation signs.
• Renal function at intervals during prolonged infusion, particularly in cats and small dogs where the PEG vehicle dose per kg can be substantial.
• Cumulative dose documentation throughout the day. The daily ceiling is real and is easier to exceed than clinicians often expect.

Weaning

Wean by reducing the CRI rate by 25–50% every 4–6 hours once tremor activity has been absent or minimal for several hours. Some patients can transition directly from CRI to no therapy; others need a brief oral methocarbamol course (15–50 mg/kg PO q8h) as the IV is tapered, particularly in pyrethroid-toxic cats where breakthrough tremors can occur during the late phase of toxin elimination.

Watch for tremor recurrence during the taper; if the patient is still tremoring as the dose comes down, the underlying toxin is not yet sufficiently eliminated and the rate should go back up rather than continuing the taper.

Sources

• Plumb’s Veterinary Drugs, methocarbamol monograph (current edition).
• Hayes WK, Brown SR, Hodgson HA, et al. Intravenous lipid emulsion therapy for permethrin toxicosis in cats. J Vet Emerg Crit Care. 2020;30(5):608–614. (ILE adjunct in pyrethroid toxicity, alongside methocarbamol.)
• Boller M, Boller EM, Oodegard S, Otto CM. Small animal cardiopulmonary resuscitation requires a continuum of care: proposal for a chain of survival for veterinary patients. J Am Vet Med Assoc. 2012;240(5):540–554. (Tetanus management protocols using methocarbamol.)
• ASPCA Animal Poison Control Center protocols for tremorogenic toxicoses. (Standard supportive care including methocarbamol dosing.)